Roche, Novartis approvals in Europe signal more head-to-head competition

Reuters

Center

High Factuality

Private Equity: The Woodbridge Company

Roche, Novartis approvals in Europe signal more head-to-head competition

ZURICH -Swiss drugmakers Roche and Novartis each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients. Roche's Evrysdi, already approved in the United States, gained backing from the European Commission for spinal muscular atrophy (SMA), where Novartis's $2.1 million per patient gene therapy Zolgensma